- Trials with a EudraCT protocol (472)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
472 result(s) found for: Bone Density Test.
Displaying page 7 of 24.
EudraCT Number: 2020-005974-91 | Sponsor Protocol Number: CT-P41_3.1 | Start Date*: 2021-04-26 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteop... | |||||||||||||
Medical condition: Osteoporosis is a systemic skeletal disease that is characterized by low bone mass and micro architectural deterioration of bone tissue, with a low bone mineral density (BMD) and consequent increas... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003868-25 | Sponsor Protocol Number: DEN-03-IB | Start Date*: 2024-04-22 | |||||||||||
Sponsor Name:Instituto Butantan | |||||||||||||
Full Title: Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Dengue 1,2,3,4 (Attenuated) Vaccine produced by Instituto Butantan | |||||||||||||
Medical condition: Dengue | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000859-40 | Sponsor Protocol Number: AIFA-2016-02364864 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||
Full Title: A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to ad... | |||||||||||||
Medical condition: Type-2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008257-30 | Sponsor Protocol Number: 0822-042 | Start Date*: 2009-03-31 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: Estudio en fase IIa aleatorizado, doble ciego, controlado con placebo para evaluar los efectos de odanacatib (MK-0822) sobre la densidad mineral ósea (DMO) y la seguridad general en el tratamiento ... | |||||||||||||
Medical condition: Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) DE (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023122-21 | Sponsor Protocol Number: PB002 | Start Date*: 2011-11-08 | ||||||||||||||||
Sponsor Name:King's College London [...] | ||||||||||||||||||
Full Title: Pro-Bono 2- A prospective study of loss of bone mineral density in patients with HIV over time: implications for clinical practice and therapeutic options: Vitamin D sub study. | ||||||||||||||||||
Medical condition: HIV | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004110-40 | Sponsor Protocol Number: CPJMR0062101 | Start Date*: 2006-11-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Single Centre, Single Arm, Exploratory, Open Label Study to Determine the Early Bone Formation and Bone Resorption Biomarker Response Profile of a Potent Bone Anabolic Treatment (PTH-1-34) with D... | |||||||||||||
Medical condition: Osteopenic and Osteoporotic postmenopausal women | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022060-13 | Sponsor Protocol Number: MC/PR/9900/004/10 | Start Date*: 2011-11-18 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: MULTICENTRE, RANDOMIZED, OPEN-LABEL, TWO-ARM PARALLEL GROUPS, ACTIVE CONTROLLED STUDY DESIGN TO DEMONSTRATE EFFICACY AND TOLERABILITY OF CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1... | |||||||||||||
Medical condition: Postmenopausal osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: PL (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005343-23 | Sponsor Protocol Number: ADAIDO | Start Date*: 2021-05-28 | |||||||||||
Sponsor Name:IRCCS ISTITUTO ORTOPEDICO GALEAZZI S.P.A | |||||||||||||
Full Title: Effect of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non me... | |||||||||||||
Medical condition: post-menopausal osteoporosis in women with non-metastatic hormonal receptor positive (HR+) breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000730-20 | Sponsor Protocol Number: FP-001-IM | Start Date*: 2006-02-02 | |||||||||||
Sponsor Name:Nycomed Danmark Aps | |||||||||||||
Full Title: An open label, international, multi centre, parallel group, phase III b, randomised trial, investigating lumbar spine Bone Mineral Density (BMD) changes in postmenopausal women with primary osteopo... | |||||||||||||
Medical condition: Primary postmenopausal osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006315-68 | Sponsor Protocol Number: B3D-EW-GHDH | Start Date*: 2007-05-07 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: Comparison of the Effects of Teriparatide with those of Risendronate on Lumbar Spine Volumetric Bone Mineral Density in GLucocorticpid-Induced Osteoporosis in Men | ||
Medical condition: Males with glucocorticoid-induced osteoporosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Completed) GR (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003523-11 | Sponsor Protocol Number: CGP24112301 | Start Date*: 2019-08-29 | ||||||||||||||||
Sponsor Name:Hexal AG | ||||||||||||||||||
Full Title: A randomized, double-blind, multicenter integrated phase I/III study in postmenopausal women with osteoporosis to compare the pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity... | ||||||||||||||||||
Medical condition: Osteoporosis is defined as a progressive, systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: CZ (Completed) ES (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004055-20 | Sponsor Protocol Number: ICR-CTSU/2013/10040 | Start Date*: 2014-09-23 | ||||||||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust [...] | ||||||||||||||||||
Full Title: A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223. | ||||||||||||||||||
Medical condition: Castrate resistant prostate cancer with bone metastases. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005045-31 | Sponsor Protocol Number: 55668 | Start Date*: 2016-09-13 |
Sponsor Name:Erasmus MC | ||
Full Title: Switching to Tenofovir Alafenamide Fumarate or ABACavir in patients with Tenofovir Disoproxil Fumarate associated eGFR decline. A randomized clinical trial. | ||
Medical condition: Renal safety of switching from TDF to TAF or ABC in patients with TDF-associated eGFR-decline. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004835-72 | Sponsor Protocol Number: UB-MedSci-001/2004 | Start Date*: 2005-01-12 |
Sponsor Name:University of Birmingham [...] | ||
Full Title: A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascualr risk in GH deficient adults | ||
Medical condition: Growth hormone deficiency in adult life | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-004521-28 | Sponsor Protocol Number: HHSC/010 | Start Date*: 2009-06-30 |
Sponsor Name:Imperial College London | ||
Full Title: A multi-centre phase I/II safety and tolerability study following the infusion of expanded autologous progeny of an adult CD34 positive stem cell subset to patients with recent tibial fractures. | ||
Medical condition: Fractured Tibia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004545-27 | Sponsor Protocol Number: GS-US-366-1216 | Start Date*: 2015-06-16 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positiv... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002855-27 | Sponsor Protocol Number: IN-CA-311-3963/CTN299 | Start Date*: 2018-01-22 | |||||||||||
Sponsor Name:UNIVERSITY HEALTH NETWORK | |||||||||||||
Full Title: BonE health in ageING Women: Improvement or prevention of changes in Bone Mineral Density by Switching Antiretroviral Agents. Is there an optimal time to intervene? | |||||||||||||
Medical condition: HIV infection and menopause | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004131-57 | Sponsor Protocol Number: CZOL446M2309 | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG [...] | |||||||||||||
Full Title: A two year multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatmen... | |||||||||||||
Medical condition: Treatment of osteoporosis in men | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) BE (Completed) CZ (Completed) HU (Completed) DE (Completed) PT (Completed) SK (Completed) GB (Completed) IT (Completed) PL (Completed) AT (Completed) IS (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024342-30 | Sponsor Protocol Number: CBYM338X2202 | Start Date*: 2011-07-20 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled multi-center study of BYM338 for treatment of cachexia in patients with stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the panc... | |||||||||||||
Medical condition: Condition of cachexia in adults with stage IV metastatic non-small cell lung cancer or stage III/IV pancreatic adenocarcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000087-42 | Sponsor Protocol Number: TAISTR_2016 | Start Date*: 2016-05-11 |
Sponsor Name:University College Dublin | ||
Full Title: A multicentre, prospective, single arm, open-label 96 week observational trial of the tolerability, adherence and efficacy of a dolutegravir/abacavir/lamivudine single tablet regimen in HIV-1 antib... | ||
Medical condition: Human Immunodeficiency Virus (HIV) infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
